NOVEMBER 2023 – FEBRUARY 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA November 15 – Dabrafenib – LGG/HGG BRAF. The BRAF inhibitor has been approved in the European Union for the following therapeutic indications: treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy, in combination with trametinib; treatment of paediatric patients aged 1 […]